Intranasal drug administration is receiving increased attention as adelivery method for by- passing the blood–brain barrier and rapidly targeting therapeutics to the brain or CNS. The objective of the present study was to selected carbamazepine nanoemulsion for nose-to-brain delivery. Carbamazepine nanoemulsion (NE) formulation were successfully prepared by the spontaneous emulsification method (titration method) using Capmul MCM as the oil, Tween-80 as surfactant, and PEG-600 as co-surfactant phase on the basis of solubility studies. The nanoemulsion formulation containing 7.35% oil, 66.18% Smix ratio (3:1 Tween-80:PEG-600 ratio),26.47% (v/v) aqueous phase that displayed an optical transparency of 99.42±0.81%, globule size of 71.70±3.06 nm, and polydispersity index of 0.256±0.002. The selected Carbamazepine nanoemulsion was characterized, and the in-vitro drug release and in-vivo nasal absorption of drug from the selected formulation were evaluated in rats. In-vitro and ex vivo permeation studies showed an initial burst of drug release at 60 min and Carbamazepine nanoemulsion show drug release up to 5 h. In vivo pharmacokinetic studies in rats showed that Carbamazepine.